Mesenchymal Stem Cells Repress Th17 Molecular Program through the PD-1 Pathway

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Luz Crawford, Patricia ^a,d,e   Noël, Danièle ^a,b   Fernandez, Ximena ^d   Khoury, Maroun ^d   Figueroa, Fernando ^d   Carrión, Flavio ^d   Jorgensen, Christian ^a,b,c   Djouad, Farida ^a,b  

^a INSERM   (France)

^b UNIV MONTPELLIER   (France)

^c LAPEYRONIE HOSPITAL   (France)

^d UNIVERSIDAD DE LOS ANDES   (Chile)

^e UNIVERSIDAD DE SANTIAGO DE CHILE   (Chile)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; GAMMA INTERFERON; INTERLEUKIN 17; NITRIC OXIDE; PROGRAMMED DEATH 1 RECEPTOR; PROSTAGLANDIN E2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ARTICLE; CD4+ T LYMPHOCYTE; CELL CONTACT; CELL CULTURE; CELL FUNCTION; CELL LINEAGE; CELL MATURATION; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; FEMALE; MALE; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; POLARIZATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; STROMA CELL; TH1 CELL; TH17 CELL; UPREGULATION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD274; CELL COMMUNICATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; DIFFUSION CHAMBERS, CULTURE; GENE EXPRESSION REGULATION; INTERLEUKIN-17; MESENCHYMAL STROMAL CELLS; MICE; PROGRAMMED CELL DEATH 1 RECEPTOR; SIGNAL TRANSDUCTION; TH1 CELLS; TH17 CELLS;

EID: 84866458557     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045272     Document Type: Article

References (46)

1. Mariani E, Facchini A, (2012) Clinical applications and biosafety of human adult mesenchymal stem cells. Curr Pharm Des 18: 1821-45.
2. Djouad F, Bouffi C, Ghannam S, Noel D, Jorgensen C, (2009) Mesenchymal stem cells: innovative therapeutic tools for rheumatic diseases. Nat Rev Rheumatol 5: 392-9.
3. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, et al. (2002) Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 30: 42-8.
4. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, et al. (2003) Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102: 3837-44.
5. Ren G, Su J, Zhao X, Zhang L, Zhang J, et al. (2008) Apoptotic cells induce immunosuppression through dendritic cells: critical roles of IFN-gamma and nitric oxide. J Immunol 181: 3277-84.
6. Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, et al. (2008) Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood 111: 1327-33.
7. Selmani Z, Naji A, Zidi I, Favier B, Gaiffe E, et al. (2008) Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 26: 212-22.
8. Hegyi B, Kudlik G, Monostori E, Uher F, (2012) Activated T-cells and pro-inflammatory cytokines differentially regulate prostaglandin E2 secretion by mesenchymal stem cells. Biochem Biophys Res Commun 419: 215-20.
9. Nemeth K, Leelahavanichkul A, Yuen PS, Mayer B, Parmelee A, et al. (2009) Bone marrow stromal cells attenuate sepsis via prostaglandin E(2)-dependent reprogramming of host macrophages to increase their interleukin-10 production. Nat Med 15: 42-9.
10. Augello A, Tasso R, Negrini SM, Amateis A, Indiveri F, et al. (2005) Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 35: 1482-90.
11. Sheng H, Wang Y, Jin Y, Zhang Q, Zhang Y, et al. (2008) A critical role of IFNgamma in priming MSC-mediated suppression of T cell proliferation through up-regulation of B7-H1. Cell Res 18: 846-57.
12. Xue Q, Luan XY, Gu YZ, Wu HY, Zhang GB, et al. (2010) The negative co-signaling molecule b7-h4 is expressed by human bone marrow-derived mesenchymal stem cells and mediates its T-cell modulatory activity. Stem Cells Dev 19: 27-38.
13. English K, Ryan JM, Tobin L, Murphy MJ, Barry FP, et al. (2009) Cell contact, prostaglandin E(2) and transforming growth factor beta 1 play non-redundant roles in human mesenchymal stem cell induction of CD4+CD25(High) forkhead box P3+ regulatory T cells. Clin Exp Immunol 156: 149-60.
14. Gonzalez MA, Gonzalez-Rey E, Rico L, Buscher D, Delgado M, (2009) Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses. Gastroenterology 136: 978-89.
15. Boumaza I, Srinivasan S, Witt WT, Feghali-Bostwick C, Dai Y, et al. (2009) Autologous bone marrow-derived rat mesenchymal stem cells promote PDX-1 and insulin expression in the islets, alter T cell cytokine pattern and preserve regulatory T cells in the periphery and induce sustained normoglycemia. J Autoimmun 32: 33-42.
16. Madec AM, Mallone R, Afonso G, Abou Mrad E, Mesnier A, et al. (2009) Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells. Diabetologia 52: 1391-9.
17. Wang J, Wang G, Sun B, Li H, Mu L, et al. (2008) Interleukin-27 suppresses experimental autoimmune encephalomyelitis during bone marrow stromal cell treatment. J Autoimmun 30: 222-9.
18. Bouffi C, Bony C, Courties G, Jorgensen C, Noel D, (2010) IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS One 5: e14247.
19. Zhao W, Wang Y, Wang D, Sun B, Wang G, et al. (2008) TGF-beta expression by allogeneic bone marrow stromal cells ameliorates diabetes in NOD mice through modulating the distribution of CD4+ T cell subsets. Cell Immunol 253: 23-30.
20. Ghannam S, Pene J, Torcy-Moquet G, Jorgensen C, Yssel H, (2010) Mesenchymal stem cells inhibit human Th17 cell differentiation and function and induce a T regulatory cell phenotype. J Immunol 185: 302-12.
21. Darlington PJ, Boivin MN, Renoux C, Francois M, Galipeau J, et al. (2010) Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosis. Ann Neurol 68: 540-5.
22. Duffy MM, Ritter T, Ceredig R, Griffin MD, (2011) Mesenchymal stem cell effects on T-cell effector pathways. Stem Cell Res Ther 2: 34.
23. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP, (2002) Prostaglandins as modulators of immunity. Trends Immunol 23: 144-50.
24. Esaki Y, Li Y, Sakata D, Yao C, Segi-Nishida E, et al. (2010) Dual roles of PGE2-EP4 signaling in mouse experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A 107: 12233-8.
25. Yao C, Sakata D, Esaki Y, Li Y, Matsuoka T, et al. (2009) Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion. Nat Med 15: 633-40.
26. Kalinski P, (2012) Regulation of immune responses by prostaglandin E2. J Immunol 188: 21-8.
27. Boniface K, Bak-Jensen KS, Li Y, Blumenschein WM, McGeachy MJ, et al. (2009) Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling. J Exp Med 206: 535-48.
28. Napolitani G, Acosta-Rodriguez EV, Lanzavecchia A, Sallusto F, (2009) Prostaglandin E2 enhances Th17 responses via modulation of IL-17 and IFN-gamma production by memory CD4+ T cells. Eur J Immunol 39: 1301-12.
29. Valdez PA, Vithayathil PJ, Janelsins BM, Shaffer AL, Williamson PR, et al. (2012) Prostaglandin E2 Suppresses Antifungal Immunity by Inhibiting Interferon Regulatory Factor 4 Function and Interleukin-17 Expression in T Cells. Immunity 4: 668-79.
30. Keir ME, GFreeman GJ, Sharpe AH, (2007) PD-1 regulates self-reactive CD8+ T cell responses to antigen in lymph nodes and tissues. J Immunol 179: 5064-70.
31. Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, et al. (2004) PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 64: 1140-5.
32. Chen L, (2004) Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol 4: 336-47.
33. Stagg J, Pommey S, Eliopoulos N, Galipeau J, (2006) Interferon-gamma-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. Blood 107: 2570-7.
34. English K, Barry FP, Field-Corbett CP, Mahon BP, (2007) IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells. Immunol Lett 110: 91-100.
35. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, et al. (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8: 315-7.
36. Miranda KM, Espey MG, Wink DA, (2001) A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite. Nitric Oxide 5: 62-71.
37. Keir ME, Butte MJ, Freeman GJ, Sharpe AH, (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26: 677-704.
38. Francisco LM, Salinas VH, Brown KE, Vanguri VK, Freeman, et al, (2009) PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 206: 3015-29.
39. Tatara R, Ozaki K, Kikuchi Y, Hatanaka K, Oh I, et al. (2011) Mesenchymal stromal cells inhibit Th17 but not regulatory T-cell differentiation. Cytotherapy 13: 686-94.
40. Duffy MM, Pindjakova J, Hanley SA, McCarthy C, Weidhofer GA, et al. (2011) Mesenchymal stem cell inhibition of T-helper 17 cell- differentiation is triggered by cell-cell contact and mediated by prostaglandin E2 via the EP4 receptor. Eur J Immunol 41: 2840-51.
41. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, et al. (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 92: 1027-34.
42. Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, et al. (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8: 793-800.
43. Sumpter TL, Thomson AW, (2011) The STATus of PD-L1 (B7-H1) on tolerogenic APCs. Eur J Immunol 41: 286-90.
44. Wolfle SJ, Strebovsky J, Bartz H, Sahr A, Arnold C, et al. (2010) PD-L1 expression on tolerogenic APCs is controlled by STAT-3. Eur J Immunol 41: 413-24.
45. Rodriguez-Garcia M, Porichis F, de Jong OG, Levi K, Diefenbach TJ, et al. (2011) Expression of PD-L1 and PD-L2 on human macrophages is up-regulated by HIV-1 and differentially modulated by IL-10. J Leukoc Biol 89: 507-15.
46. Ghannam S, Bouffi C, Djouad F, Jorgensen C, Noel D, (2010) Immunosuppression by mesenchymal stem cells: mechanisms and clinical applications. Stem Cell Res Ther 1: 2.